** Shares of medical device maker Dexcom DXCM.O fall 3.9% to $74.82 premarket
** Late on Friday, DXCM said it had received a warning letter from the U.S. FDA following inspections of its two manufacturing facilities in San Diego, California and Mesa, Arizona
** Company said it has already submitted responses to the so-called "Form 483" and is currently preparing a written response
** A Form 483 is an agency report that includes "observations" made by FDA inspectors regarding practices or conditions they find "objectionable
** Stock has fallen 41.6% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。